Therefore, pharmacologically enhancing SIRT1 activity to promote FoxO1 deacetylation may therapeutically ameliorate renal lipid dysmetabolism in DKD, offering novel biological targets and therapeutic rationale. Here, FOXO1 is linked to diabetic kidney disease.